EyePoint Pharmaceuticals Sees Dramatic Stock Surge Following Positive Study Results
Company’s Advancements in Eye Treatment Spur Investor Confidence
EyePoint Pharmaceuticals (EYPT) experienced a significant increase of 27.6% in its stock price during the latest trading session, closing at $12.12. This surge occurred alongside a notable rise in trading volume, indicating heightened interest from investors. The stock has also gained 19.1% over the last month, showcasing a strong upward trend.
Earlier this week, EyePoint Pharmaceuticals shared encouraging interim results from the 16-week phase II VERONA study, which is assessing its lead candidate, Duravyu, for treating diabetic macular edema. Additionally, the company reported that the first patient has been dosed in the phase III LUGANO study, which focuses on treating wet age-related macular degeneration with Duravyu. The optimistic outlook surrounding these developments likely contributed to the stock’s impressive rally.
EyePoint is projected to report a quarterly loss of $0.52 per share in its upcoming earnings report, a decline of 57.6% compared to last year. Revenue expectations stand at $10.83 million, reflecting a 28.8% decrease from the same quarter a year prior.
While anticipated earnings and revenue growth play a crucial role in assessing stock potential, research indicates a strong link between earnings estimate revisions and short-term stock price movements. For EyePoint Pharmaceuticals, the consensus earnings per share (EPS) estimate has remained stable over the past 30 days. A stock’s price typically doesn’t continue to rise without trends in earnings estimates, making EyePoint a company to watch in the near future to see if this recent momentum continues.
Currently, the stock holds a Zacks Rank of #3 (Hold). For investors looking to explore more opportunities, today’s Zacks Rank #1 (Strong Buy) stocks can be found here >>>>
EyePoint Pharmaceuticals operates within the Zacks Medical – Biomedical and Genetics industry. Qiagen (QGEN), another company in this sector, finished the last trading session down slightly, closing 0.6% higher at $41.80, and has reported an overall return of -8.2% over the past month.
For Qiagen, the EPS estimate for its upcoming earnings report remains unchanged at $0.54, representing a 3.9% increase from the previous year. The company currently carries a Zacks Rank of #4 (Sell).
Expert Analysts Recommend Top Growth Picks
Five analysts from Zacks have identified their top stock picks, each expected to potentially double in value in the coming months. Among these, Director of Research Sheraz Mian has selected one company showing the most significant growth potential.
This particular company is appealing to millennial and Gen Z markets, having generated nearly $1 billion in revenue during the last quarter. Following a recent stock pullback, experts suggest it could be an optimal time to invest. Not all of Zacks’ selections are guaranteed winners, but this one has the potential to outperform previous picks like Nano-X Imaging, which surged by 129.6% in just over nine months.
To access the complete list of recommended stocks, including the top pick, click to download the report: 5 Stocks Set to Double.
EYEPOINT PHARMACEUTICALS, INC. (EYPT): Free Stock Analysis Report
QIAGEN N.V. (QGEN): Free Stock Analysis Report
To read the original article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are those of the author and do not necessarily reflect the views of Nasdaq, Inc.
